FINWIRES · TerminalLIVE
FINWIRES

Scotiabank Sees Canadian Dollar Strength As USD Weakness Supports Outlook, Targets USDCAD At 1.33 By End-2026

By

-- Scotiabank continues to expect broad-based weakness for the U.S. dollar (USD) against all of the major developed economy currencies, supporting its outlook for a stronger Canadian dollar (CAD).

The divergence in policy rate paths remains a core pillar of its fundamental outlook, the bank said in its latest foreign exchange outlook, adding that the USD outlook remains weak through the second half of 2026 and into the end of our forecast horizon at the end of 2027.

Meanwhile, CAD continues to make "halting progress" toward Scotiabank's forecast targets as it continues to retrace its 2024-2025 decline.

CAD made a fresh cycle high in early January, only to relinquish its early gains in the initial weeks of the US/Iran conflict that began in early March, said Eric Theoret, associate director for global foreign exchange at Scotiabank.

"The CAD's recent gains have delivered a meaningful narrowing in the discount (USDCAD premium) to our fair value estimate. Fundamentals argue for a stronger CAD, and we anticipate medium-term strength as markets shake off their conflict-related concerns,"

"The Bank of Canada forecast is also directionally unchanged, however the 75bps of cumulative tightening have been pulled forward into 2026 while leaving the terminal rate unchanged at 3.00%. Our USDCAD forecast is unchanged, and we continue to target 1.33 by the end of 2026 and 1.30 by the end of 2027," added Theoret.

However, Scotiabank maintained that trade policy uncertainty remains a major risk into the July 1 review of the USMCA.

Related Articles

Research

Research Alert: CFRA Lowers View On Bio-rad Laboratories To Sell From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $45 to $235, reflecting a 25.6x multiple of our 2026 EPS estimate (down to $9.17 from $10.15; we cut our 2027 EPS estimate to $9.97 from $10.68), a discount to BIO's three-year historical forward average of 29.5x. Rather than a dramatic cut to National Institutes of Health (NIH) funding, Congress approved a modest increase for 2026 funding, helping reduce research budget concerns that loomed during 2025. However, BIO and peers anticipate that research spending growth from academic and early-stage biotech could remain muted over the near term as academic institutions adjust. The outlook for 2026 anticipates ongoing pressure, with BIO cutting sales and margin expectations during the Q1 earnings report, citing headwinds arising from the U.S.-Iran conflict in the Middle East such as weaker diagnostics sales and higher freight and fuel costs.

$BIO
Insider Trading

Comfort Systems USA Insider Sold Shares Worth $889,890, According to a Recent SEC Filing

Pablo G. Mercado, Director, on April 30, 2026, sold 500 shares in Comfort Systems USA (FIX) for $889,890. Following the Form 4 filing with the SEC, Mercado has control over a total of 3,000 common shares of the company, with 3,000 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1035983/000153524626000004/xslF345X05/form4-05012026_040501.xml

$FIX
Insider Trading

Kaiser Aluminum Insider Sold Shares Worth $524,757, According to a Recent SEC Filing

Keith Harvey, Director, President & CEO, on April 29, 2026, sold 3,031 shares in Kaiser Aluminum (KALU) for $524,757. Following the Form 4 filing with the SEC, Harvey has control over a total of 94,308 common shares of the company, with 94,308 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/811596/000119312526201545/xslF345X05/ownership.xml

$KALU